Prelude Therapeutics Inc (PRLD) Profit Margins
Over the twelve months to 2026-06-30, Prelude Therapeutics Inc (PRLD) had operating margin -300.6%, net margin -269.7%, free cash flow margin -148.3%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PRLDPrelude Therapeutics IncFollow PRLD — free
—
Price chart with a free account
- Market cap
- 289.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Operating margin | -1995.9% | -861.3% | -300.6% | |
| Net margin | -1816.8% | -819.6% | -269.7% | |
| FCF margin | -1480.7% | -464.3% | -148.3% |
USD millions · SEC XBRL
Prelude Therapeutics Inc — questions
- What is Prelude Therapeutics Inc's operating margin?
- -300.6% over the twelve months to 2026-06-30.
- What is Prelude Therapeutics Inc's net profit margin?
- -269.7% over the twelve months to 2026-06-30.
Every figure on this page comes from Prelude Therapeutics Inc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.